Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Pharmacokinetics parameters were regarded as exploratory parameters. Adverse event data will be covered in Adverse events section.
Inclusion Criteria:
Exclusion Criteria:
Higashiibaraki, Ibaraki 311-3193, Japan
Sunto, Shizuoka 411-8611, Japan
Arakawa-ku, Tokyo 116-8567, Japan
Shinjuku-ku, Tokyo 162-8666, Japan